Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center

Table 3 Adverse events during chemotherapy by grade, n (%)

	Grade
	1	2	3	4
Neutropenia	3 (7.9)	1 (2.6)	2 (5.3)	1 (2.6)
Hand-foot syndrome	5 (13.2)	1 (2.6)
Hypertransaminasemia	3 (7.9)	2 (5.3)
Nausea	4 (10.5)		1 (2.6)
Peripheral neuropathy	4 (10.5)	1 (2.6)
Vomiting	4 (10.5)	1 (2.6)
Anemia	2 (5.3)		1 (2.6)	1 (2.6)
Asthenia	4 (10.5)
Constipation	4 (10.5)
Thrombocytopenia			2 (5.3)	2 (5.3)
Anorexia	3 (7.9)
Diarrhea	2 (5.3)
Sialorrhea	2 (5.3)
Hyperbilirubinemia	1 (2.6)